Effects of statin treatment on primary and hospital care use: a microsimulation model
Zhou J. et al, (2025)
Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a de novo discrete event simulation model.
Zhou J. et al, (2025), Br J Psychiatry, 227, 545 - 552
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
Zhou J. et al, (2025), EClinicalMedicine
Medication adherence and costs of medical care among patients with Parkinson's disease: an observational study using electronic medical records.
Yi Z. et al, (2024), BMC Public Health, 24
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial.
Zhou J. et al, (2024), Pharmacoeconomics, 42, 261 - 273
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study
MIHAYLOVA B. et al, (2024), The Lancet Regional Health - Europe
Effects of Empagliflozin on Health Care Use and Quality of Life in CKD in the United Kingdom: Results from EMPA-KIDNEY
Zhou J. and Mihaylova BN., (2024), JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 35
Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
Wu R. et al, (2023), British Journal of General Practice
A systematic review of the factors associated with suicide attempts among sexual-minority youth
Wang XX. et al, (2023), The European Journal of Psychiatry, 37, 72 - 83
Cost-effectiveness of endovascular thrombectomy with alteplase versus endovascular thrombectomy alone for acute ischemic stroke secondary to large vessel occlusion.
Ye Z. et al, (2023), CMAJ Open, 11, E443 - E450
Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis.
Wang K. et al, (2023), Front Aging Neurosci, 15
Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK
Zhou J. et al, (2022), PharmacoEconomics
Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study
Wu R. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2850 - 2850
CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA
Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16
Cost-effectiveness of statin therapy in categories of patients in the UK
Mihaylova B. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2841 - 2841
EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS
Zhou J. et al, (2022), VALUE IN HEALTH, 25, S12 - S12
Impact of cardiovascular events on primary and hospital care costs: findings from UK Biobank study
Zhou J. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2852 - 2852
P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments
Zhou J. et al, (2022), Value in Health, 25, S12 - S12
P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data
Wu R. et al, (2022), Value in Health, 25, S16 - S16